### Scientific Sessions and Main Program

**Saturday (27.10.2018)**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>07:30</td>
<td>Welcome Reception</td>
</tr>
<tr>
<td>08:45</td>
<td>08:45 – 10:15 Workshops</td>
</tr>
<tr>
<td>09:00</td>
<td>Radiotherapy in Salvage (J. Hortzsch-Schulze, M. T. Nakajima)</td>
</tr>
<tr>
<td>09:15</td>
<td>Molecular Pathogenesis (M. J. Hansmann, C. Stedile)</td>
</tr>
<tr>
<td>09:30</td>
<td>Developing Health Care Environments (A. Hagenbeek, G. Henke)</td>
</tr>
<tr>
<td>09:45</td>
<td>Positron Emission Tomography (M. Dietlein, M. Mägert)</td>
</tr>
<tr>
<td>10:15</td>
<td>Coffee Break</td>
</tr>
<tr>
<td>10:30</td>
<td>10:30 – 12:00 Workshops</td>
</tr>
<tr>
<td>11:15</td>
<td>Biosimilar Rituximab – a New Treatment Option by Sanofi Germany (A. Engel)</td>
</tr>
<tr>
<td>11:30</td>
<td>Biomolecular Development in Oncology (T. Dörger)</td>
</tr>
<tr>
<td>11:45</td>
<td>Treatment of DLBCL positive, lymphocyte-predominant Hodgkin lymphoma (O. Echderer)</td>
</tr>
<tr>
<td>12:00</td>
<td>Lunch</td>
</tr>
<tr>
<td>13:45</td>
<td>Coffee Break</td>
</tr>
<tr>
<td>14:00</td>
<td>14:00 – 15:30 Immunotherapy – Biomechanics (A. Rosenwald, M. Shipp)</td>
</tr>
<tr>
<td>15:30</td>
<td>Oral Abstract Presentations</td>
</tr>
<tr>
<td>16:00</td>
<td>16:00 – 17:30 Advanced Hodgkin lymphoma: How Can We Do Better? by Yokeda/Medscap (M. Hertzberg)</td>
</tr>
<tr>
<td>17:30</td>
<td>Coffee Break</td>
</tr>
<tr>
<td>17:45</td>
<td>Opening Ceremony</td>
</tr>
</tbody>
</table>

**Sunday (28.10.2018)**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>07:30</td>
<td>Welcome Reception</td>
</tr>
<tr>
<td>08:45</td>
<td>08:45 – 10:15 Oncology Meets Autoimmunity by Chugui (A. Engel)</td>
</tr>
<tr>
<td>09:00</td>
<td>Autoimmunology in systemic sclerosis (J. Henes)</td>
</tr>
<tr>
<td>09:15</td>
<td>Autoimmunity in chronic GHD (B. Wolff)</td>
</tr>
<tr>
<td>10:15</td>
<td>Coffee Break</td>
</tr>
<tr>
<td>10:30</td>
<td>10:30 – 12:00 Biology &amp; Microenvironment (A. van den Berg, C. Steidl)</td>
</tr>
<tr>
<td>11:30</td>
<td>Microenvironment (R. Köpper)</td>
</tr>
<tr>
<td>11:45</td>
<td>Genotyping of cHL via liquid biopsy (B. Ross)</td>
</tr>
<tr>
<td>12:00</td>
<td>Oral Abstract Presentations</td>
</tr>
<tr>
<td>13:45</td>
<td>Coffee Break</td>
</tr>
<tr>
<td>14:00</td>
<td>14:00 – 15:30 Early Stages (R. Hoppe, J. Römers)</td>
</tr>
<tr>
<td>15:30</td>
<td>Early-Stage Favorable HL: HD16 (A. Engel)</td>
</tr>
<tr>
<td>16:00</td>
<td>FOCUS2: Randomized Phase II Trial (M. Andrelo)</td>
</tr>
<tr>
<td>17:30</td>
<td>Coffee Break</td>
</tr>
<tr>
<td>17:45</td>
<td>Closing Remarks</td>
</tr>
</tbody>
</table>

**Monday (29.10.2018)**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>07:30</td>
<td>Welcome Reception</td>
</tr>
<tr>
<td>08:45</td>
<td>08:45 – 10:15 CAR T Cell Therapies: Hype or Hope? by Celgene (H. Einsele)</td>
</tr>
<tr>
<td>09:00</td>
<td>Preclinical Rationale for CAR T Cell Therapy (S. Thomas)</td>
</tr>
<tr>
<td>09:15</td>
<td>CD39 directed CAR T Cell Therapy in B-NHL (P. Borchmann)</td>
</tr>
<tr>
<td>10:15</td>
<td>RCMA directed CAR T Cell Therapy in MM (N. Einsele)</td>
</tr>
<tr>
<td>10:30</td>
<td>Coffee Break</td>
</tr>
<tr>
<td>10:45</td>
<td>10:45 – 12:00 Pediatric HL (C. Mazu-Perlitz, K. M. Kelly)</td>
</tr>
<tr>
<td>11:30</td>
<td>POI1-L1 Expression in Pediatric HL (C. Gattinon)</td>
</tr>
<tr>
<td>11:45</td>
<td>Genotyping in Familial HL (O. Yang)</td>
</tr>
<tr>
<td>12:00</td>
<td>Functional and Financial Outcomes after Treatment for Pediatric Hodgkin lymphoma (J. Pansoni)</td>
</tr>
<tr>
<td>12:15</td>
<td>12:15 – 13:45 Checkpointblockade in Lymphomas by MSD (A. Engel)</td>
</tr>
<tr>
<td>13:45</td>
<td>Basics in immunotherapy for lymphomas (B. Wolff)</td>
</tr>
<tr>
<td>14:00</td>
<td>PD-1 blockade current and future aspects of cHL therapy (P. Borchmann)</td>
</tr>
<tr>
<td>15:30</td>
<td>PD-1 blockade in NHLs (P. L. Zinzani)</td>
</tr>
<tr>
<td>16:00</td>
<td>16:00 – 17:30 Relapsed/Refractory HL (C. M. Hsokowski, A. Sureda)</td>
</tr>
<tr>
<td>17:30</td>
<td>BRaVE: Phase II Trial (A. Hagenbeek)</td>
</tr>
<tr>
<td>17:45</td>
<td>Novel Agents in First Line Salvage (R. Advani)</td>
</tr>
<tr>
<td></td>
<td>Oral Abstract Presentations</td>
</tr>
</tbody>
</table>
CONFERENCE COMMITTEE

Organizing Committee
Andreas Engert, MD, Symposium and GHSG Chairman
Sven Borchmann, MD, Symposium Secretary
Paul J. Bröckelmann, MD, Symposium Secretary
Dennis A. Eichenauer, MD, Symposium Secretary

German Hodgkin Study Group
Department I for Internal Medicine
University Hospital of Cologne
Kerpener Straße 62, D–50924 Cologne

Phone: +49 (0) 221.478–5933
Fax: +49 (0) 221.478–3778
Email: info@hodgkinsymposium.org
Further Information: www.hodgkinsymposium.org

Conference Management &
Industrial Exhibition Secretariat
Gabriele Hanke
Travel & Congress Activities
Marienburger Str. 8; D–40883 Ratingen
Phone: +49 (0) 2102.669 36
Fax: +49 (0) 2102.9648 29
Email: info@tca-hanke.de

INTERNATIONAL
SCIENTIFIC COMMITTEE
R. Advani, M. André, S. Ansell, P. Armand, J. Armitage,
O. Baiocchi, M. Björkholm, P. Borchmann, P. Brice,
O. Casasnovas, B. Cheson, J. Connors, V. Diehl, M. Dietlein,
H. T. Eich, M. Federico, J. Friedberg, A. Hagenbeek,
M. L. Hansmann, M. Hertzberg, R. Hoppe, M. Hutchings,
T. Illidge, P. Johnson, R. Küppers, A. Lister, S. Marnitz–Schulze,
C. Mauz–Körholz, C. H. Moskowitz, A. Polliack, J. Radford,
J. Raemaekers, A. Rosenwald, M. Shipp, Y. Song, L. Specht,
C. Steidl, A. Sureda, A. van den Berg, F. van Leeuwen,
J. Walewski, W. Wilson, J. Yahalom, A. Younes, J. Zijlstra,
P. L. Zinzani
ACKNOWLEDGEMENTS

We wish to express our appreciation and gratitude to our partners.

ACADEMIC SPONSORS

DFG Deutsche Forschungsgemeinschaft

Financial support was kindly provided by the Deutsche Forschungsgemeinschaft (DFG) within their program “International Scientific Events”.

Karl Musshoff Stiftung

The Karl Musshoff Stiftung kindly supports the Karl Musshoff Prize in the categories “Basic and Translational Science” and “Clinical Research” as well as the “Young Investigator Awards”.

B. BRAUN-STIFTUNG

DER GESUNDHEIT NEUWE WEGE BEREITEN

Financial support was kindly provided by the B. Braun-Stiftung within their program “Scientific events”.

ACADEMIC PARTNERS

Certified with 23 credit points by the European Association for Haematopathology

Astromec GmbH
www.astrazeneca.de

Novartis Pharma GmbH
www.novartis.de

Sanofi Genzyme GmbH
www.sanofi.de
EXHIBITION HALL
The scientific exhibition takes place at the Gürzenich Conference Center in the “Isabellensaal” on the first floor.

Opening hours of the Exhibition
Saturday, October 27, 2018 12:00 –18:00
Sunday, October 28, 2018 08:00 –18:00
Monday, October 29, 2018 08:00 –18:00

1. Takeda Oncology
2. Bristol-Myers Squibb GmbH & Co. KGaA
3. Sanofi Genzyme GmbH
4. AstraZeneca GmbH
5. Roche Pharma AG
6. Novartis Pharma GmbH
7. MSD SHARP & DOHME GmbH
8. Deutsche Leukämie- & Lymphom-Hilfe e.V.
9. Leukämiehilfe RHEIN-MAIN e.V.
<table>
<thead>
<tr>
<th>SECTION</th>
<th>PAGE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Conference and Scientific Committee</td>
<td>3</td>
</tr>
<tr>
<td>Sponsors</td>
<td>Acknowledgements</td>
</tr>
<tr>
<td>Exhibition</td>
<td>6–7</td>
</tr>
<tr>
<td>Table of Contents</td>
<td>9</td>
</tr>
<tr>
<td>Welcome</td>
<td>11</td>
</tr>
<tr>
<td>General Information</td>
<td>12–15</td>
</tr>
<tr>
<td>Scientific Program</td>
<td></td>
</tr>
<tr>
<td><strong>Saturday 27.10.2018</strong></td>
<td>18–23</td>
</tr>
<tr>
<td>Workshops</td>
<td>Scientific Program</td>
</tr>
<tr>
<td><strong>Sunday 28.10.2018</strong></td>
<td>24–28</td>
</tr>
<tr>
<td>Scientific Program</td>
<td>Poster Session</td>
</tr>
<tr>
<td><strong>Monday 29.10.2018</strong></td>
<td>29–33</td>
</tr>
<tr>
<td>Scientific Program</td>
<td>Poster Session</td>
</tr>
<tr>
<td>Oral and Poster Presentations</td>
<td></td>
</tr>
<tr>
<td>WS: Molecular Pathogenesis</td>
<td>35</td>
</tr>
<tr>
<td>Immunotherapy – Biomechanisms</td>
<td>36</td>
</tr>
<tr>
<td>Biology and Microenvironment</td>
<td>37–40</td>
</tr>
<tr>
<td>Early Stages</td>
<td>41–43</td>
</tr>
<tr>
<td>Survivorship and Patients’ Perspective</td>
<td>44–50</td>
</tr>
<tr>
<td>Advanced Stages</td>
<td>51–56</td>
</tr>
<tr>
<td>Pediatric Hodgkin Lymphoma</td>
<td>56–59</td>
</tr>
<tr>
<td>Immunotherapy – Clinical</td>
<td>59–60</td>
</tr>
<tr>
<td>Relapsed/Refractory HL</td>
<td>61–67</td>
</tr>
<tr>
<td>Speakers and Chairs</td>
<td>69–71</td>
</tr>
<tr>
<td>Award Winners ISHL11</td>
<td>72–73</td>
</tr>
<tr>
<td>FSA-Kodex</td>
<td>74</td>
</tr>
<tr>
<td>Advertisements</td>
<td>75–76</td>
</tr>
</tbody>
</table>
Dear Colleagues and Friends,

We warmly welcome you to our 11th International Symposium on Hodgkin Lymphoma (ISHL11), hosted by the German Hodgkin Study Group (GHSG). This Symposium has become the central forum for clinicians and scientists involved in Hodgkin Lymphoma research and therapy, enabling in-depth exchange of the latest results and new ideas. Discussing the relevance of new findings for daily clinical practice in Hodgkin Lymphoma is one of the major goals of this Symposium. It will once more be held at the Gürzenich Conference Center in Cologne, which provides a wonderful communicative environment for discussion and networking.

ISHL11 will cover the most recent results in basic research, diagnostics and treatment of Hodgkin Lymphoma and related malignancies. Scientific symposia and workshops will complement the program. This year’s core topic will be survivorship. The Karl Musshoff Prize in the categories “Basic and Translational Science” and “Clinical Research” will be presented during the opening ceremony. On top of that, five Young Investigator Awards have been selected by an international committee, based on the evaluation of their abstracts.

We thank all our contributors and cordially welcome you to ISHL11!

Andreas Engert
Symposium Chairman

Sven Borchmann
Paul J. Bröckelmann
Dennis A. Eichenauer
Symposium Secretary
Conference Secretariat
Gürzenich Cologne | Martinstraße 29–37 | 50667 Cologne

During the conference, you can contact the Secretariat at
Phone: +49 (0) 173 . 939 07 30
Email: info@tca-hanke.de

Opening Hours of the Conference Secretariat
Saturday, October 27, 2018 07:00 – 18:00
Sunday, October 28, 2018 07:00 – 19:00
Monday, October 29, 2018 07:00 – 18:00

Accommodation
If you still need a hotel room, please contact the conference management:
Phone: +49 (0) 2102 . 669 36
Email: info@tca-hanke.de

Name Badge
Please make sure to always wear your badge at the conference. If you lose your badge, we will have to charge you a replacement fee.

Catering
During the breaks, complimentary coffee, fruit and refreshments will be available, and other small snacks can be bought. For participants of the scientific symposia, breakfast and lunch will be provided.

Insurance
The meeting organizers cannot accept liability for personal injuries sustained to Conference participants or for loss or damage of their personal belongings, neither during nor as a result of the meeting.

Internet
There will be free wifi at the Gürzenich Conference Center. Further details and access codes will be provided on site. You can also use the two on-site internet terminals for web browsing and web-based email access.

Prayer Room
A nondenominational prayer room will be available in the conference center. For further details, please contact the Conference Secretariat.
**Registration**

Pre-registration will close on **October 26, 2018**. All registrations received on or after **October 27** will be considered as on-site registrations and will be charged the on-site fee. Full registration will include access to the scientific sessions and exhibition, a copy of the program, the welcome reception on **Saturday** (**October 27**) and all refreshment breaks. You will also receive a name tag; please wear this name tag at all conference events including the scientific symposia. No refunds will be given.

**Speakers Ready Room**

The Speakers Ready Room is located next to the registration desk on the ground floor of the Gürzenich Conference Center. Speakers are requested to hand in their PowerPoint presentations in 16:9 format saved on a stick at least 3 hours before their session or the day before if the session starts early in the morning. We can only accept Windows PowerPoint files for upload to the conference system. It is not permitted to use your own laptops or other devices for uploading the files.

**Non-Smoking**

Please note that there will be a strict non-smoking policy at all conference facilities.

**Transportation**

The airports closest to Cologne City are Cologne Bonn Airport (CGN; 15km) and Düsseldorf Airport (DUS; 45km). From Cologne Bonn Airport you can reach Cologne central station by regional rail in about 30 minutes; from Frankfurt Airport to Cologne it takes only an hour by InterCity Express (ICE) and from Düsseldorf Airport about 45 minutes. Cologne central station is within walking distance (about 10 minutes) from the Gürzenich Conference Center and the Dorint Hotel. You can also take bus no. 132 and get off at “Gürzenichstraße”. The other hotels recommended by the Conference Organization can easily be reached by public transport. Cologne has an efficient public transport system, but the recommended hotels, the venue as well as other places of interest are within a comfortable walking distance from each other. For those who are traveling by car, we recommend to use the parking ground “Heumarkt” (about 3 minutes walking distance from the Gürzenich).

If you want to take a taxi, you can either get in directly at one of the numerous taxi stands or you can order a taxi by phone from one of the taxi call centres.

**Welcome Reception**

On Saturday evening, the conference will be opened officially. After the Opening Ceremony, all participants are warmly invited to join us at our Get Together event at the Gürzenich Conference Center. This event is a great opportunity to meet and chat with many colleagues involved in Hodgkin lymphoma research and treatment. Drinks and snacks will be provided.
The Gürzenich and Cologne

The Gürzenich Conference Center is situated right in the heart of Cologne, an ideal location to explore all the different facets of one of the liveliest cities in Germany.

The Conference Site: Completed in 1447, the Gürzenich was the largest secular building of the city built in the middle ages. It has a Gothic façade and a spectacular roof lined with turrets. It was used to receive many guests that were deemed very important, including kings and queens.

The Old Town: Located between the lovely Rhine embankment promenade and the world famous Cologne Cathedral, the old town offers a lovely backdrop for a walk. If you are ready for a bit of exercise, you might like to climb the cathedral tower to get a stunning bird’s eye view of the town. The Farina House just across the Gürzenich is the birthplace of the famous Eau de Cologne. It shows a major part of Cologne’s economic and social history by way of the perfume industry. If you walk a bit further along the Rhine towards the South end of the city, you will see a shiny glass building right on the banks of the river. It houses the unique Chocolate Museum – a very nice place for a relaxing break.

Culture: Kolumba, the art museum of the archbishop of Cologne, is both an architectural and a cultural highlight. It is a fascinating new building designed by Peter Zumthor and houses an impressive collection of art from ancient times to the present day. Another place worth a visit is the Museum Ludwig, where you can find one of the most distinguished collections of 20th century art, ranging from Russian avant-garde to works of famous contemporary artists.

Beer Culture: The place to dive into Cologne’s beer culture is Brauhaus Früh. If you prefer a cosier place, you could try Altstadt Päffgen. Both offer traditional, local meals that will keep you going for a long time.

Shopping: The main shopping streets are Schildergasse and Hohe Straße. If you are looking for smaller, more exclusive boutique shops, we recommend to visit the Mittelstraße. In Germany, shops usually do not open on Sundays, however, the shopping arcade at the train station is open 7 days a week.
### Workshop 1 (parallel sessions)  **08:45–10:15**

**Radiotherapy in Salvage**  
**DORINT HOTEL: MARTIN / AUGUSTIN**

- **08:45–09:00**  
  Radiotherapy for salvage – Principles and ILROG guidelines  
 Louis Constine (Rochester, US)

- **09:00–09:15**  
  Radiotherapy techniques for salvage and re-irradiation  
  Bouthaina Dabaja (Houston, US)

- **09:15–09:30**  
  Long-term considerations in salvage therapy  
  Lena Specht (Copenhagen, DK)

- **09:30–09:45**  
  Radiation- and immunotherapy for relapsed or refractory HL  
  Christian Baues (Cologne, DE)

- **09:45–10:00**  
  Future of RT in Salvage – new approaches, alternatives to high dose chemotherapy  
  Joachim Yahalom (New York, US)

- **10:00–10:15**  
  Panel discussion  
  Led by Simone Marnitz-Schulze and Joachim Yahalom

### Workshop 2 (parallel sessions)  **08:45–10:15**

**Molecular Pathogenesis**  
**ROOM: KLEINER SAAL**

- **08:45–09:05**  
  Somatic gene mutations in NLPHL and THRBCL  
  Sylvia Hartmann and Bianca Schuhmacher (Frankfurt a.M., DE)

- **09:05–09:25**  
  Microenvironment biology and outcome prediction in pediatric Hodgkin lymphoma  
  Anja Mottok (Ulm, DE)

- **09:45–10:00**  
  CK2A is overexpressed, active and targetable with silmitasertib in classical Hodgkin lymphoma  
  Andrea Visentin (Padova, IT)

- **09:00–09:25**  
  T001 Abstract Talk  
  Low B–cell content at diagnosis is associated with adverse outcome in advanced stage classical Hodgkin lymphoma  
  Wolfram Klapper (Kiel, DE)

- **09:25–09:45**  
  T002 Abstract Talk  
  ROR–1 receptor is a potential therapeutic target in classical Hodgkin lymphoma  
  George Rassidakis (Stockholm, SE)

### Workshop 3 (parallel sessions)  **08:45–10:15**

**Developing Health Care Environments**  
**ROOM: MARSILIUSSAAL**

- **08:45–09:05**  
  Challenges at a developing cancer center in East Africa  
  Oliver Henke (Moshi, TZ)

- **09:05–09:25**  
  Takeda Access to Medicine Program in Subsaharan Africa  
  Judith Kinley (Cambridge, US)

- **09:25–09:45**  
  Hodgkin Lymphoma care in current Venezuela  
  Maria Alejandra Torres Viera (Caracas, VE)

- **09:45–10:15**  
  Panel discussion  
  Led by Anton Hagenbeek and Oliver Henke

### Workshop 4 (parallel sessions)  **08:45–10:15**

**Positron Emission Tomography**  
**ROOM: GROSSE SAAL**

- **08:45–09:15**  
  PET / CT – The perspective from the German Hodgkin Study Group  
  Carsten Kobe (Cologne, DE)

- **09:15–09:45**  
  PET guided strategy in Hodgkin lymphoma: issues and perspectives  
  Andrea Gallamini (Nice, FR)

- **09:45–10:15**  
  Measurement of metabolic volume and threshold in Hodgkin Lymphoma: how to move to a standard  
  Olivier Casasnovas (Dijon, FR)

### Workshop 5 (parallel sessions)  **10:30–12:00**

**Survivorship**  
**ROOM: KLEINER SAAL**

- **10:30–10:45**  
  Genetic determinants of radiation-induced breast cancer after HL  
  Flora van Leeuwen (Amsterdam, NL)

- **10:45–11:00**  
  Genetic polymorphisms associated with anthracycline-induced cardiotoxicity  
  Leszek Wojnowski (Mainz, DE)

- **11:00–11:15**  
  Genetic determinants of for acute radiation toxicity  
  Catharine West (Manchester, UK)

- **11:15–11:30**  
  Genetic susceptibility for treatment–related adverse effects: How can we make significant progress?  
  Lindsay Morton (Bethesda, US)

- **11:30–12:00**  
  Panel discussion
### Workshop 6 (parallel sessions) 10:30–12:00

**Immunotherapy: Chances & Pitfalls**  
**Room:** Großer Saal  
**Speakers:** Philippe Armand (Boston, US), Tim Illidge (Manchester, UK)

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Presenter(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:30–11:00</td>
<td>The role of radiotherapy for Hodgkin lymphoma in the era of PD-1 blockade</td>
<td>Tim Illidge (Manchester, UK)</td>
</tr>
<tr>
<td>11:00–11:30</td>
<td>Impact of PD-1 blockade on the treatment landscape of Hodgkin lymphoma</td>
<td>Philippe Armand (Boston, US)</td>
</tr>
<tr>
<td>11:30–12:00</td>
<td>Pitfalls in clinical trial design and interpretation with immunotherapy</td>
<td>Steve Ansell (Rochester, US)</td>
</tr>
</tbody>
</table>

### Workshop 7 (parallel sessions) 10:30–12:00

**Challenges in Older Lymphoma Patients**  
**Room:** Marsiliussaal  
**Speakers:** Pauline Brice (Paris, FR), Jonathan Friedberg (Rochester, US)

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Presenter(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:30–10:45</td>
<td>The role of geriatric assessments in lymphoma</td>
<td>Alessandra Tucci (Brescia, IT)</td>
</tr>
<tr>
<td>10:45–11:00</td>
<td>Chemotherapy combinations in elderly HL</td>
<td>Pauline Brice (Paris, FR)</td>
</tr>
<tr>
<td>11:00–11:15</td>
<td>German experience in elderly HL</td>
<td>Boris Böll (Cologne, DE)</td>
</tr>
<tr>
<td>11:15–11:30</td>
<td>Brentuximab combinations in elderly HL, including checkpoint inhibitor</td>
<td>Jonathan Friedberg (Rochester, US)</td>
</tr>
<tr>
<td>11:30–11:45</td>
<td>Brentuximab / chemotherapy combinations in elderly HL</td>
<td>Andrew Evens (New Jersey, US)</td>
</tr>
<tr>
<td>11:45–12:00</td>
<td>Panel discussion</td>
<td>Led by Pauline Brice and Jonathan Friedberg</td>
</tr>
</tbody>
</table>

### Workshop 8 (parallel sessions) 10:30–12:00

**Minimum Residual Disease**  
**Room:** Dorint Hotel: Martin / Augustin  
**Speakers:** Anton Hagenbeek (Amsterdam, NL), Pier Luigi Zinzani (Bologna, IT)

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Presenter(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:30–10:50</td>
<td>Total metabolic tumor volume, circulating tumor cells, cell-free DNA: distinct prognostic value in FL</td>
<td>Marie Helene Delfau–Larue (Paris, FR)</td>
</tr>
<tr>
<td>10:50–11:10</td>
<td>The role of ctDNA in research and decision making- Lessons from ctDNA in DLBCL</td>
<td>Mark Roschewski (Bethesda, US)</td>
</tr>
<tr>
<td>11:10–11:30</td>
<td>The Hodgkin Lymphoma MRD consortium</td>
<td>Sven Borchmann (Cologne, DE), Michiel Pegtel (Amsterdam, NL)</td>
</tr>
<tr>
<td>11:30–12:00</td>
<td>Panel discussion</td>
<td>Led by Pier-Luigi Zinzani and Anton Hagenbeek</td>
</tr>
</tbody>
</table>

### Scientific Symposium (Sandoz Germany) 12:15–13:45

**Biosimilar Rituximab – a New Treatment Option**  
**Room:** Großer Saal  
**Speakers:** Andreas Engert (Cologne, DE), Theodor Dingermann (Frankfurt a.M., DE), N. N., Dennis A. Eichenauer (Cologne, DE)

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Presenter(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:15–12:45</td>
<td>Biosimilar Development in Oncology</td>
<td>Theodor Dingermann (Frankfurt a.M., DE)</td>
</tr>
<tr>
<td>12:45–13:15</td>
<td>Clinical evidence for biosimilar rituximab</td>
<td>N. N.</td>
</tr>
</tbody>
</table>
### Scientific Session 1  
**14:00–15:30**

**Immunotherapy – Biomechanisms**  
**Room: Grosser Saal**

- **14:00–14:20**  
  **T-cells and PD1 Inhibition in cHL**  
  Margaret Shipp (Boston, US)

- **14:20–14:40**  
  **Immune Evasion**  
  Maher K. Gandhi (Brisbane, AU)

- **14:40–14:50**  
  **Expression of PD-1 and PD-L1 increase in multiple consecutive biopsies in patients with classical Hodgkin lymphoma, Ingrid Glimelius (Uppsala, SE)**

- **14:50–15:00**  
  **Trabectedin inhibits classical Hodgkin lymphoma growth, monocytes immunosuppressive polarization by tumor cells and synergizes with the CCR5-antagonist Maraviroc, Naike Casagrande (Aviano, IT)**

- **Poster Pitch | P002**  
  Development of an α-CD30 bispecific antibody immunotherapy for Hodgkin lymphoma, Cindy L. Schwartz (Milwaukee, US)

- **15:05–15:15**  
  **The peripheral blood neutrophil PD-L1 and lymphocyte PD-1 axis in classical Hodgkin lymphoma at diagnosis, Annarosa Cuccaro (Rome, IT)**

- **15:15–15:25**  
  **PD-L1+ and IDO-1+ tumor-associated macrophages predict survival in primary classical Hodgkin lymphoma, Kristiina Karihtala (Helsinki, FI)**

### Scientific Symposium  
**16:00–17:30**

(Developed by Medscape Education, supported by Takeda)

**Advanced Hodgkin Lymphoma: How Can We Do Better?**  
**Room: Grosser Saal**

- **16:00–16:10**  
  **Introduction**  
  Mark Hertzberg (Sydney, AU)

- **16:10–16:30**  
  **Can we do better in front-line?**  
  Astrid Pavlovsky (Buenos Aires, AR)

- **16:30**  
  **Audience Q&A with panel discussion**

- **16:35–16:55**  
  **Can we do better with salvage?**  
  Craig H. Moskowitz (Miami, US)

- **16:55**  
  **Audience Q&A with panel discussion**

- **17:00–17:20**  
  **Assessing risk of failure throughout treatment**  
  Martin Hutchings (Copenhagen, DK)

- **17:20**  
  **Audience Q&A with panel discussion**

- **17:25**  
  **Conclusion**  
  Mark Hertzberg (Sydney, AU)
Scientific Session 2 07:30–09:00

Interactive Case Discussions [ROOM: GROSSER SAAL]

**Faculty:** Mark Hertzberg (Sydney, AU), Andrew Lister (London, UK)

**Presenters:** Dennis A. Eichenauer (Cologne, DE), Joanna Romejko-Jarosinska (Warsaw, PL), Otavio Baiocchi (São Paulo, BR), Sven Borchmann (Cologne, DE)

Presentation of difficult and controversial Hodgkin Lymphoma cases with a focus on interaction and discussion
1. Stage IV NLPHL (D. A. Eichenauer)
2. Elderly chL (J. Romejko-Jarosinska)
3. HIV-positive HL (O. Baiocchi)
4. Progress on anti-PD1 moAb (S. Borchmann)

Scientific Symposium 09:15–10:15

(Chugai)

**Oncology Meets Autoimmunity [ROOM: GROSSER SAAL]**

Andreas Engert (Cologne, DE)

09:15–09:45  
Autotransplant in systemic sclerosis  
Jörg Henes (Tübingen, DE)

09:45–10:15  
Autoimmunity in chronic GVHD  
Daniel Wolff (Regensburg, DE)

Scientific Session 3 10:30–12:00

**Biology & Microenvironment [ROOM: GROSSER SAAL]**

Anke van den Berg (Groningen, NL), Christian Steidl (Vancouver, CA)

10:30–10:50  
Microenvironment  
Ralf Küppers (Essen, DE)

10:50–11:10  
Genotyping of chL via Liquid Biopsy  
Davide Rossi (Bellinzona, CH)

11:10–11:20 | T008  
Genotyping circulating tumor DNA of pediatric Hodgkin lymphoma patients to determine pathogenic mechanisms and monitor therapy, Andreas Bräuninger (Gießen, DE)

11:20–11:30 | T009  
Circulating tumor DNA as a biomarker for the noninvasive genotyping and monitoring of classical Hodgkin Lymphoma, Ranjana Advani (Stanford, US)

11:40–11:50 | T010  
Clinical validation of an extracellular vesicle associated miRNA detection assay to monitor therapy response in classical Hodgkin Lymphoma patients, Esther Drees (Amsterdam, NL)

11:50–12:00 | T011  
Molecular mechanisms in the pathogenesis of composite lymphomas, Anna Lollies (Essen, DE)

Scientific Symposium 12:15–13:45

(Takeda)

**Tailoring Sequencing and Treatment Targets [ROOM: GROSSER SAAL]**

Peter Borchmann (Cologne, DE)

12:15–12:20  
Welcome and introduction  
Peter Borchmann (Cologne, DE)

12:20–12:35  
Considering consolidation after autologous stem cell transplantation  
Daniel Molin (Uppsala, SE)

12:35–12:50  
Relapse after autologous transplant: options and optimising outcomes  
Anna Sureda (Barcelona, ES)

12:50–13:00  
Considering patient factors: challenging cases and clinical management  
All, facilitated by Peter Borchmann (Cologne, DE)

13:40–13:45  
Summary and close  
Peter Borchmann (Cologne, DE)
### Scientific Session 4 14:00–15:30

**Early Stages**  *ROOM: GROSSER SAAL*

Richard Hoppe (Stanford, US), John Raemaekers (Nijmegen, NL)

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:00–14:20</td>
<td>Early-Stage Favorable HL: HD16</td>
<td>Andreas Engert (Cologne, DE)</td>
<td></td>
</tr>
<tr>
<td>14:20–14:40</td>
<td>BREACH: Randomized phase II trial</td>
<td>Marc André (Yvoir, BE)</td>
<td></td>
</tr>
</tbody>
</table>

**Poster Session**  *GÜRZENICH, KLEINER SAAL* 15:30–16:00

Please join the poster presentation and take the chance to discuss the results with your colleagues.

### Scientific Symposium 16:00–17:30

*(Bristol-Myers Squibb)*

**Focus on cHL: Current Insights and Future Perspectives**  *ROOM: GROSSER SAAL*

Peter Borchmann (Cologne, DE)

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>16:00–16:05</td>
<td>Welcome and Introduction</td>
<td>Peter Borchmann (Cologne, DE)</td>
<td></td>
</tr>
<tr>
<td>16:05–16:25</td>
<td>The Evolving cHL Treatment Landscape</td>
<td>Graham Collins (Oxford, UK)</td>
<td></td>
</tr>
<tr>
<td>16:25–16:45</td>
<td>Understanding the Unmet Needs in cHL</td>
<td>Peter Borchmann (Cologne, DE)</td>
<td></td>
</tr>
<tr>
<td>16:45–17:05</td>
<td>Focus on Biomarkers: Biology as a Key Driver of Therapeutic Benefit</td>
<td>Margaret Shipp (Boston, US)</td>
<td></td>
</tr>
<tr>
<td>17:05–17:25</td>
<td>Panel Discussion</td>
<td>All</td>
<td></td>
</tr>
<tr>
<td>17:25–17:30</td>
<td>Concluding Remarks</td>
<td>Peter Borchmann (Cologne, DE)</td>
<td></td>
</tr>
<tr>
<td>Time</td>
<td>Session</td>
<td>Title</td>
<td>Speaker</td>
</tr>
<tr>
<td>------------</td>
<td>----------------------------------------------</td>
<td>----------------------------------------------------------------------</td>
<td>----------------------------------</td>
</tr>
<tr>
<td>17:45 –19:15</td>
<td>Scientific Session 5</td>
<td><strong>Survivorship &amp; Patients’ Perspective</strong>&lt;br&gt;Room: Grosser Saal&lt;br&gt;Flora van Leeuwen (Amsterdam, NL), Ananda Plate (Munich, DE)</td>
<td>Lorna Warwick (Toronto, CA)</td>
</tr>
<tr>
<td>17:45 –18:05</td>
<td>What Patients Really Want: The Global Lymphoma Patient Survey</td>
<td>Lorna Warwick (Toronto, CA)</td>
<td>Hans Knoop (Amsterdam, NL)</td>
</tr>
<tr>
<td>18:25 –18:45</td>
<td>Genetic Susceptibility</td>
<td>Lindsay Morton (Bethesda, US)</td>
<td></td>
</tr>
<tr>
<td>18:45 –18:55</td>
<td>Employment situation among long-term Hodgkin Lymphoma survivors in Europe: an analysis of patients from nine consecutive EORTC-LYSA trials</td>
<td>Maja Maraldo (Copenhagen, DK)</td>
<td></td>
</tr>
<tr>
<td>17:45 –19:15</td>
<td>Poster Pitch</td>
<td>Early-stage Hodgkin lymphoma (HL) in the modern era: harnessing simulation modeling to delineate long-term patient outcomes</td>
<td>Andrew Evens (Boston, US)</td>
</tr>
<tr>
<td>18:55 –19:05</td>
<td>Baseline PET features as predictors of outcome in advanced HL: a prospective evaluation of UK patients in the RATHL trial (CRUK/07/033)</td>
<td>Sally Barrington (London, UK)</td>
<td></td>
</tr>
<tr>
<td>19:05 –19:15</td>
<td>Contemporarily treated Hodgkin lymphoma patients have childbearing potential in line with matched comparators</td>
<td>Ingrid Glimelius (Stockholm, SE)</td>
<td></td>
</tr>
<tr>
<td>19:00 –21:00</td>
<td>Scientific Symposium</td>
<td><strong>CAR T Cell Therapies: Hype or Hope?</strong>&lt;br&gt;Room: Grosser Saal&lt;br&gt;Hermann Einsele (Würzburg, DE)</td>
<td></td>
</tr>
<tr>
<td>07:30 –09:00</td>
<td>Advanced Stages</td>
<td><strong>Advanced Stages</strong>&lt;br&gt;Room: Grosser Saal&lt;br&gt;Volker Diehl (Cologne, DE), Peter Johnson (Southampton, UK)</td>
<td>John Radford (Manchester, UK)</td>
</tr>
<tr>
<td>07:30 –07:50</td>
<td>ECHELON1 Update</td>
<td>John Radford (Manchester, UK)</td>
<td></td>
</tr>
<tr>
<td>07:50 –08:10</td>
<td>HD18 Update</td>
<td>Peter Borchmann (Cologne, DE)</td>
<td></td>
</tr>
<tr>
<td>08:10 –08:30</td>
<td>LYSAL2011 Phase III Study</td>
<td>Olivier Casasnovas (Dijon, FR)</td>
<td></td>
</tr>
<tr>
<td>18:45 –18:55</td>
<td>B-CAP (brentuximab vedotin, cyclophosphamide, doxorubicin and prednisolone) in older patients with advanced-stage Hodgkin lymphoma: results of a phase II intergroup trial by the German Hodgkin Study Group (GHSG) and the Nordic Lymphoma Group (NLG)</td>
<td>Alexander Fosså (Oslo, NO)</td>
<td></td>
</tr>
<tr>
<td>08:50 –09:00</td>
<td>CAR T Cell Therapies: Hype or Hope?</td>
<td></td>
<td></td>
</tr>
<tr>
<td>09:15 –10:15</td>
<td>CAR T Cell Therapies: Hype or Hope?</td>
<td></td>
<td></td>
</tr>
<tr>
<td>09:15 –10:15</td>
<td>CAR T Cell Therapies: Hype or Hope?</td>
<td>Hermann Einsele (Würzburg, DE)</td>
<td>Simone Thomas (Regensburg, DE)</td>
</tr>
<tr>
<td>09:15 –10:15</td>
<td>CAR T Cell Therapies: Hype or Hope?</td>
<td>Hermann Einsele (Würzburg, DE)</td>
<td></td>
</tr>
<tr>
<td>09:15 –10:15</td>
<td>CAR T Cell Therapies: Hype or Hope?</td>
<td>Hermann Einsele (Würzburg, DE)</td>
<td>Peter Borchmann (Cologne, DE)</td>
</tr>
<tr>
<td>09:15 –10:15</td>
<td>CAR T Cell Therapies: Hype or Hope?</td>
<td>Hermann Einsele (Würzburg, DE)</td>
<td></td>
</tr>
</tbody>
</table>
### Scientific Session 7  
**10:30 – 12:00**

**Pediatric HL**  
**ROOM: GROSSER SAAL**

Christine Mauz-Körholz (Gießen, DE), Kara M. Kelly (New York, US)

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:30 – 10:50</td>
<td>PD1/L1 Expression in Pediatric HL</td>
<td>Stefan Gattenlöhner (Gießen, DE)</td>
<td></td>
</tr>
<tr>
<td>10:50 – 11:10</td>
<td>Genotyping in Familial HL</td>
<td>Jun Yang (Memphis, US)</td>
<td></td>
</tr>
<tr>
<td>11:10 – 11:30</td>
<td>Functional and Financial Outcomes after Treatment for Pediatric Hodgkin Lymphoma</td>
<td>Susan Parsons (Boston, US)</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:40 – 11:50</td>
<td>Safety and early response to the first 2 cycles of Brentuximab Vedotin substituting vincristine in the OEPACOPDAC regimen for high risk pediatric Hodgkin lymphoma (HL)</td>
<td>Monika Metzger (Memphis, US)</td>
<td></td>
</tr>
<tr>
<td>11:50 – 12:00</td>
<td>The feasibility of deep inspiration breath-hold in children: results of the TEDDI pilot study</td>
<td>Maja Maraldo (Copenhagen, DK)</td>
<td></td>
</tr>
</tbody>
</table>

---

### Scientific Symposium  
**12:15 – 13:45**

**Checkpointblockade in Lymphomas**  
**ROOM: GROSSER SAAL**

Andreas Engert (Cologne, DE)

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:15 – 12:35</td>
<td>Basics in immunotherapy for lymphomas</td>
<td>Dominik Wolf (Innsbruck, AT)</td>
<td></td>
</tr>
<tr>
<td>12:35 – 12:55</td>
<td>PD-1 blockade current and future aspects of cHL therapy</td>
<td>Peter Borchmann (Cologne, DE)</td>
<td></td>
</tr>
<tr>
<td>12:55 – 13:15</td>
<td>PD-1 blockade in NHLs</td>
<td>Pier Luigi Zinzani (Bologna, IT)</td>
<td></td>
</tr>
</tbody>
</table>

---

### Scientific Session 8  
**14:00 – 15:30**

**Immunotherapy – Clinical**  
**ROOM: GROSSER SAAL**

Philippe Armand (Boston, US), Martin Hutchings (Copenhagen, DK)

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:00 – 14:20</td>
<td>Checkmate 205: Cohort D</td>
<td>Steve Ansell (Rochester, US)</td>
<td></td>
</tr>
<tr>
<td>14:20 – 14:40</td>
<td>Toxicities from Checkpoint Inhibitor Therapy: Diagnosis, Management and Follow-up</td>
<td>Paul J. Bröckelmann (Cologne, DE)</td>
<td></td>
</tr>
<tr>
<td>14:40 – 14:50</td>
<td>Brentuximab Vedotin in combination with Nivolumab in patients with relapsed/refractory Hodgkin lymphoma: follow-up results from the phase 1/2 study</td>
<td>Alex Herrera (Duarte, US)</td>
<td></td>
</tr>
<tr>
<td>14:50 – 15:00</td>
<td>A phase II study of SHR-1210, an anti-PD-1 antibody, in Chinese patients with relapsed/refractory classic Hodgkin lymphoma</td>
<td>Yuqin Song (Beijing, CN)</td>
<td></td>
</tr>
</tbody>
</table>

---

### Poster Session  
**GÜRZENICH, KLEINER SAAL**  
**15:30 – 16:00**

Please join the poster presentation and take the chance to discuss the results with your colleagues.
Scientific Session 9 16:00–17:30

**Relapsed/Refractory HL**  
**ROOM: GROSSER SAAL**

Craig H. Moskowitz (Miami, US), Anna Sureda (Barcelona, ES)

16:00–16:20  
**BRaVE: Phase II Trial**  
Anton Hagenbeek  
(Amsterdam, NL)

16:20–16:40  
**Novel Agents in First Line Salvage**  
Ranjana Advani  
(Stanford, US)

16:40–16:50 | T029  
Second autologous stem cell transplantation (ASCT) for relapsed or refractory (r/r) Hodgkin Lymphoma (HL) after a previous autograft: a registry study of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation,  
Carmen Martínez (Barcelona, ES)

16:50–17:00 | T030  
Bendamustine, gemcitabine, and dexamethasone (BGD) chemotherapy followed by autologous stem cell transplantation (ASCT) is effective treatment for patients with relapsed/refractory Hodgkin lymphoma (rHL) – Results of the Polish Lymphoma Research Group (PLRG) pilot study – Pre-PLRG-HL1 (BURGUND),  
Ewa Paszkiewicz-Kozik (Warsaw, PL)

17:10–17:20 | T031  
Five-year progression-free survival outcomes from a pivotal phase 3 study of consolidative Brentuximab Vedotin after autologous stem cell transplant in patients with Hodgkin lymphoma at risk of relapse or progression (AETHERA),  
Craig H. Moskowitz (Miami, US)

17:20–17:30 | T032  
Relapse after early-stage favorable Hodgkin lymphoma: disease characteristics, treatment strategies and their outcome,  
Paul J. Bröckelmann (Cologne, DE)

**Closing Remarks**  
**ROOM: GROSSER SAAL**  
17:45

Andreas Engert (Cologne, DE)
ABSTRACTS
ORAL AND POSTER PRESENTATIONS

Posters will be displayed in the “Kleiner Saal” on Sunday (October 28) and Monday (October 29).

Poster presenters are kindly asked to be present at their poster boards during the Poster Sessions on Sunday (October 28) and Monday (October 29), 15:30 to 16:00 to discuss their research.

WS: Molecular Pathogenesis
(Biology and Microenvironment)

Talk

◊ T001 (0006)
CK2A is overexpressed, active and targetable with silmitasertib in classical Hodgkin lymphoma

◊ T002 (0076)
Low B-cell content at diagnosis is associated with adverse outcome in advanced stage classical Hodgkin lymphoma

◊ T003 (0171)
ROR-1 receptor is a potential therapeutic target in classical Hodgkin lymphoma
Session 1: Immunotherapy – Biomechanisms

Talk

○ T004 (0051)
Expression of PD-1 and PD-L1 increase in multiple consecutive biopsies in patients with classical Hodgkin Lymphoma
Glimelius I, Amini RM, Ginman B, Molin D, Enblad G, Hollander P

○ T005 (0077)
Trabectedin inhibits classical Hodgkin Lymphoma growth, monocytes immunosuppressive polarization by tumor cells and synergizes with the CCR5-antagonist Maraviroc
Casagrande N, Borghese C, Mariotto E, Vicenzetto C, Favero A, Aldinucci D
*CB and NC co-first authors

○ T006 (0079)
The peripheral blood neutrophil PD-L1 and lymphocyte PD-1 axis in classical Hodgkin lymphoma at diagnosis

○ T007 (0079)
PD-L1+ and IDO-1+ tumor-associated macrophages predict survival in primary classical Hodgkin Lymphoma
Karihtala K, LeivonenSK, Pellinen T, Brück O, Karjalainen-Lindsberg ML, Mustjoki S, Leppä S

Poster Pitch

○ P002 (0061)
Development of an α–CD30 bispecific antibody immunotherapy for Hodgkin Lymphoma
Schwartz CL, Oldham RAA, Faber ML, Thakur A, Lum LG, Medin JA

Session 3: Biology and Microenvironment

Talk

○ T008 (0050)
Genotyping circulating tumor DNA of pediatric Hodgkin Lymphoma patients to determine pathogenic mechanisms and monitor therapy

○ T009 (0083)
Circulating tumor DNA as a biomarker for the noninvasive genotyping and monitoring of classical Hodgkin Lymphoma

Posters

P001 (0015)
Hodgkin’s variant of Richter transformation in the Czech Republic

P003 (0157)
Microsatellite and chromosomal instability constitute two mechanisms that independently lead to genomic instability in Hodgkin Lymphoma
Clinical validation of an extracellular vesicle associated miRNA detection assay to monitor therapy response in classical Hodgkin lymphoma patients

Molecular mechanisms in the pathogenesis of composite lymphomas

Poster Pitch

Functional analysis of CD30 in Hodgkin and anaplastic large cell lymphoma cell lines by CRISPR/Cas9-mediated gene knockout
Weiß AL, Lollies A, Kretzmer F, Weniger MA, Küppers R

Copy number aberrations in cell-free DNA of Hodgkin Lymphoma
Buedts L, Tousseyn T, GheySENS 0, Finalet-Ferreiro J, Dehaspe L, Verhoef G, Smits S, Vermeesch J, Vandenberghe P

Posters

Array-based DNA methylome analyses of classical Hodgkin Lymphoma

The role of TCF3 in classical Hodgkin lymphoma
Veenstra R, Kluiver J, Visser L, Diepstra A, van den Berg A

Recurrent exportin 1 mutations in patients with classical Hodgkin lymphoma

TARC immunohistochemistry in the diagnosis of classical Hodgkin lymphoma
Veldman C, Rosati S, van den Berg A, Visser L, Plattel W, Diepstra A

Whole-slide-image analysis of the tumormicronenvironment in classical Hodgkin Lymphoma

CD2 is an important adhesion molecule in the initial interaction between Hodgkin Reed-Sternberg cells and rosetting T cells
Veldman J, van den Berg A, Visser L, Diepstra A

A new reliable and highly specific antibody to detect SOCS1 (silencer of cytokine signaling 1)
Weissinger SE, Zahn M, Mellert K, Marienfeld R, Moldenhauer G, Möller P.

Soluble cytokines in Hodgkin Lymphoma patients treated with a GHSG policy: an analysis of the Czech Hodgkin Lymphoma Study Group
P013 (0088)  
Digital image analysis of the microenvironment in classical Hodgkin Lymphoma comparing primary tumor and relapse  

P014 (0098)  
CD47 is expressed on Hodgkin Reed Sternberg cells in classical Hodgkin lymphoma  

P015 (0100)  
Characterization of T-cell phenotypes with clinical significance in patients with classical Hodgkin lymphoma  
Karihtala K, Leivonen SK, Pellinen T, Brück O, Karjalainen–Lindsberg ML, Mustjoki S, Leppä S

P016 (0104)  
Phenotypic characterization of circulating T and NK cells in Hodgkin lymphoma patients in relation to tumor burden and treatment  

P017 (0120)  
Immunologic biomarkers of response and resistance to brentuximab vedotin in patients with relapsed or refractory classical Hodgkin lymphoma  
Song JY, Chan WC, Warden C, Wu X, Weisenburger DD, Chen R, Herrera AF

P018 (0139) withdrawn  
GATA3 expression distinguishes classic Hodgkin Lymphoma from nodular lymphocyte Hodgkin Lymphoma  

P020 (0164)  
Extracellular circulating DNA in Hodgkin lymphoma patients: biological correlates and prognostic impact  
Dujmović D, Bašić Kinda S, Radman I, Lauc G, Ilić I, Aurer I

P022 (0170)  
The tumor suppressor SAMHD1 is downregulated by MYC in classical Hodgkin lymphoma  
Xagoraris I, Vassilakopoulos T, Herold N, Tsesmetzis N, Khoury J, Drakos E, Rassidakis G

Session 4: Early Stages

Talk

T012 (0066)  
Relapses in early PET-negative stage I/II Hodgkin lymphoma (HL) after combined modality treatment or chemotherapy only in the EORTC/LYSA/FIL H10 trial  

T013 (0095)  
Maximum tumour dimension at baseline is associated with event–free survival in PET negative patients with stage IA / IIA Hodgkin lymphoma in the UK NCRI RAPID trial  

T014 (0118)  
Multicentric Italian experience in treatment of nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) in the Rituximab era  
**Poster Pitch**

**P027 (0101)**
Cardiovascular radiation dosimetry and predicted cardiovascular risks from involved field radiotherapy within the UK ‘RAPID’ trial in early low-risk Hodgkin Lymphoma

**P028 (0102)**
Patterns of relapse in patients treated for early stage classical Hodgkin Lymphoma in the modern era
*Nielsen K, Maraldo MV, Berthelsen AK, Loft A, Petersen PM, Aznar MC, Vogelius IR, Brown P, Specht L*

**Posters**

**P023 (0003)**
Conventional vs multifractionation at radiotherapy for above diaphragm stage II Hodgkin Lymphoma: 30-year experience of single center
*Ilyin NV, Vinogradova JN, Ivanova EI*
Session 5: Survivorship and Patients’ Perspective

Talk

Q T016 (0018)
Employment situation among long-term Hodgkin Lymphoma survivors in Europe: an analysis of patients from nine consecutive EORTC-LYSA trials

Q T017 (0044)
Is routine laboratory testing useful in detecting relapse in patients with classic Hodgkin Lymphoma in first remission?

Q T018 (0140)
Contemporarily treated Hodgkin Lymphoma patients have childbearing potential in line with matched comparators
Weibull CE, Johansson ALV, Eloranta S, Smedby KE, Björkholm M, Lambert PC, Dickman PW, Glimelius I

Poster Pitch

Q P036 (0023)
Early-stage Hodgkin Lymphoma (HL) in the modern era: harnessing simulation modeling to delineate long-term patient outcomes

Q P060 (0122)
The reciprocal relation between cancer-related fatigue and physical and psychosocial functioning in survivors of Hodgkin lymphoma
Mayer A, Stadlbäumer N, Kreissl S, Müller H, Görgen H, Borchmann P

Posters

P032 (0002)
Audit of lymphoma patient group irradiated blood product policy compliance at a UK comprehensive cancer centre
Gibson J, Wells S, Jackson S, Higham P, Seal D, Linton K

P033 (0007)
Single center analysis of nodular lymphocyte predominant Hodgkin lymphoma: focus on R-ABVD and interim PET

P034 (0021)
Returning to school or work after Hodgkin Lymphoma: An EORTC-LYSA cross-sectional study

P035 (0022)
Fatigue impairment in Hodgkin and non-Hodgkin Lymphoma survivors: a joint EORTC-LYSA cross-sectional survey
P037 (0027)
The pathway to diagnosis of Hodgkin Lymphoma in South Africa: the determinants and impact of diagnostic delay

P038 (0029)
Hepatitis B virus infection is not associated with poor prognosis in Hodgkin Lymphoma patients: a case-control study
Liu W, Yang M, Wu M, Ping L, Song Y, Zhu J

P039 (0030)
Temporal trends in treatment-related incidence of diseases of the circulatory system among Hodgkin Lymphoma patients
Weibull CE, Björkholm M, Glimelius I, Lambert PC, Andersson TML, Smedby KE, Dickman PW, Eloranta S

P040 (0031)
Clinicopathological features and prognosis of 387 cases with classical Hodgkin Lymphoma from China

P041 (0034)
A study of patient and general practitioner (GP) views and experience of managed local follow-up of long term lymphoma survivors (ADAPT)
Taylor S, Goode V, White E, Cowan R, Yorke J, Radford J

P042 (0035)
Anemia has a negative impact on the outcome of patients with Hodgkin Lymphoma

P043 (0039)
Clinical characteristics and prognostic factors of primary extranodal classical Hodgkin Lymphoma: a retrospective study of 27 cases

P044 (0046)
Investigation the role of adding a serum biomarker to interim PET/CT in Hodgkin Lymphoma patients
Jóna A, Husi K, Nagy B, Fejes Z, Miltényi Z, Illés A

P045 (0047)
Hyperlipoproteinemia and markers of atherosclerosis progression in long-term survivors of Hodgkin Lymphoma in childhood or adolescence and in healthy controls
Cepelova M, Kruseova J, Luks A, Cepela P, Potockova J, Kraml P

P046 (0052)
No clinical signals of drug – drug interaction of NEPA (netupitant + palonosetron) in cHL patients receiving ABVD regimen: a single-center real life experience
Zilioli VR, Minga P, Crucitti L, Meli E, Rusconi C, Cairoli R

P047 (0058)
An epidemiological study of Hodgkin's Lymphoma from a single tertiary care centre in India with study of disease outcome
Sen A, Dolai TK, Baul SN, Mandal PK, De R, Dutta S, Chakrabarti P

P048 (0065)
Mature oocytes cryopreservation: a feasible fertility preservation technique in adult Hodgkin lymphoma female patients

P049 (0072)
Results of cardiovascular screening in the BETER survivorship care initiative for Hodgkin Lymphoma
Pereboom SR, Nijdam A, Aleman BMP, van der Maazen RWM, Zijlstra JM, de Weijer RJ, van ’t Veer MB, Raemaekers JMM, van Leeuwen FE, on behalf of the BETER consortium
P050 (0075)
Clinical characteristics and prognosis analysis of early-stage classical Hodgkin lymphoma

P051 (0080)
Cardiovascular disease risk after treatment-induced premature ovarian insufficiency in female survivors of Hodgkin lymphoma
Aleman BMP, Krul IM, Opstal-van Winden AWJ, Janus CPM, Daniëls LA, Appelman Y, Maas AHEM, van Nimwegen FA, de Vries S, Hauptmann M, Jóźwiak K, van Leeuwen FE

P052 (0082)
Combined prognostic role of biomarkers and PET/CT in patients with Hodgkin lymphoma
Husi K, Illés A, Nagy B, Fejes Z, Bedekovics J, Miltényi Z

P053 (0091)
Neutrophil to lymphocyte ratio predicts overall survival in newly diagnosed Hodgkin lymphoma patients – single centre experience
Hajder J, Stanisavljević N, Marisavljević D, Jurišić V, Marković O, Zivković R

P054 (0092)
Pregnancy in patients in complete remission after Hodgkin lymphoma: clinical features and outcome
Gaudio F, Nardelli C, Perrone T, Laddaga FE, Specchia G

P055 (0096)
Health-related quality of life (HRQL) trajectories during treatment for advanced stage pediatric Hodgkin lymphoma (HL)

P056 (0097)
Cognitive dysfunction after treatment for Hodgkin lymphoma
Magyari F, Ivánka T, Égerházi A, Simon Z, Miltényi Z, Kósa K, Illés A

P057 (0108)
Cognitive impairments in patients with Hodgkin’s lymphoma
Vinokurova EG, Marchenko AA, Khrushchev SO, Olexenko LV, Rupchev GE, Vybornykh DE, Moiseeva TN

P058 (0109)
Fertility in Hodgkin’s lymphoma patients after initial therapy at Santa Casa de São Paulo Medical School

P059 (0114)
AA amyloidosis causing nephrotic syndrome in two patients with Hodgkin lymphoma

P061 (0125)
Chemotherapy-induced polyneuropathy in patients with Hodgkin lymphoma treated with vinca-alkaloids
Smardova L, Vlckova E, Rajdova A, Raputova J, Bednarik J, Kral Z

P062 (0134)
Long term health care use in relapsed and non-relapsed paediatric and young adult Hodgkin lymphoma patients – a population-based cohort study from Sweden and Denmark

P063 (0144)
Cognitive impairment, structural and functional brain morphological sequelae of Hodgkin lymphoma treatment. First interim results of ongoing translational study
Kozak T, Horacek J, Mockova H, Gaherova L, Fayette D, Geislerova L, Karlova I, Markova J

Oral and Poster Presentations | Survivorship and Patients’ Perspective
P064 (0146)
Cause-specific mortality among Hodgkin Lymphoma survivors up to 35 years after treatment

P065 (0150)
Elevated neutrophil-to-monocyte ratio is associated with decreased overall survival at 5 years in classic Hodgkin Lymphoma
Neves D, Roque A, Afonso C, Pinto A, Mota D, Guilherme R, Gomes M, Ribeiro L

P066 (0154)
eBEACOPP for front-line treatment of patients with classical Hodgkin Lymphoma (cHL) in the real world setting

P067 (0166)
Very late relapses (VLRS) in Hodgkin Lymphoma (HL) occurring ≥5 years after initial treatment with chemotherapy ± radiotherapy (CT±RT): Pattern of risk over 35 years and the significance of histology

Session 6: Advanced Stages

Talk

T019 (0026)
Potential impact of consolidation radiation therapy for advanced Hodgkin lymphoma: a secondary modeling analysis of SWOG S0816

T020 (0067)
Baseline PET features as predictors of outcome in advanced HL: A prospective evaluation of UK patients in the RATHL trial (CRUK/07/033)

T021 (0147)
B–CAP (brentuximab vedotin, cyclophosphamide, doxorubicin and prednisolone) in older patients with advanced-stage Hodgkin lymphoma: results of a phase II intergroup trial by the German Hodgkin Study Group (GHSG) and the Nordic Lymphoma Group (NLG)

Posters

P068 (0008)
JUNB, DUSP2, SGK1, CREBBP and SOCS1 are frequently mutated in T-cell / histiocyte rich large B-cell lymphoma
P069 (0013)
Evaluation of clinical characteristics in patients with interim-PET negative but positive end of treatment PET. Data from the prospective HD08-01 FIL study

P070 (0016)
HIV-associated Hodgkin Lymphoma at Groote Schuur Hospital, Cape Town, South Africa
Opie J, Swart L, Novitzky N

P071 (0024)
A multicenter phase 2 study of sequential brentuximab vedotin and AVD chemotherapy for older patients with untreated classical Hodgkin Lymphoma

P072 (0038)
Frontline brentuximab vedotin plus chemotherapy exhibits superior modified progression-free survival vs chemotherapy alone in patients with stage III or IV Hodgkin Lymphoma: phase 3 Echelon-1 study

P073 (0045)
BEACOPP escalated increases progression free survival in advanced classic Hodgkin Lymphoma – a single centre real life experience
Roque A, Afonso C, Neves D, Pinto A, Mota D, Guilherme R, Gomes M, Ribeiro L

P074 (0049)
Accuracy of PET-based bone marrow assessment in patients with Hodgkin lymphoma: results from the German Hodgkin Study Group trials HD16, HD17, and HD18

P075 (0055)
Should a bulky mediastinal mass larger than 7cm be considered an adverse prognostic factor in patients with advanced Hodgkin Lymphoma and negative interim PET/CT?
Lopez-Alonso R, Mashiach T, Barzilai E, Weiler-Sagie M, Dann EJ

P076 (0056)
Clinical characteristics and treatment outcome of nodular lymphocyte predominant Hodgkin’s Lymphoma with THRLBCL–like patterns
Dorokhina EI, Moiseeva TN, Kovrigina AM, Shupletsova IA, Al–Radi LS, Mangasarova YK, Goryacheva SR

P077 (0060)
Comparison immunoarchitectural patterns of primary, extranodal and bone marrow lesions in nodular lymphocyte predominant Hodgkin Lymphoma
Shupletsova I, Kovrigina A, Moiseeva T, Dorokhina E

P078 (0062)
Two distinct prognostic groups in advanced-stage Hodgkin Lymphoma revealed by the presence and site of bulky disease

P079 (0070)
German evidence-based guideline update on diagnosis, therapy and follow-up of adult Hodgkin lymphoma patients
**P080 (0071)**
Analysis of outcomes and prognostic factors of 165 newly diagnosed patients with advanced classical Hodgkin Lymphoma

**P081 (0084)**
A clinicopathologic consensus study of gray zone lymphoma (GZL) with features intermediate between diffuse large B-cell lymphoma (DLBCL) and classical HL (cHL)

**P082 (0087)**
Clinical significance of autoimmune hemolytic anaemia and autoimmune thrombocytopenia during the course of Hodgkin lymphoma
Pinczés L, Miltényi Z, Jóna A, Illés A

**P083 (0093)**
Low-dose consolidative mediastinal irradiation in accelerated hyperfractionated regimen for advanced Hodgkin Lymphoma
Bogatyreva Ti, Pavlov W, Terekhova AY, Shklyaev SS, Falaleeva NA

**P084 (0094)**
Brentuximab vedotin and bendamustine as first-line treatment of Hodgkin lymphoma in the elderly (HALO trial)

**P085 (0112)**
Treatment toxicity in elderly Hodgkin Lymphoma patients with advanced stage – multicenter retrospective data analysis from the Czech Republic

**P086 (0129)**
Metabolic tumour volume for response prediction in advanced-stage Hodgkin Lymphoma

**P087 (0135)**
Hodgkin lymphoma in HIV-positive patients: a single institution retrospective study

**P088 (0136)**
Brentuximab vedotin plus chemotherapy in patients with high-risk advanced-stage classical Hodgkin Lymphoma (cHL): results of prespecified sub-group analyses from the Echelon-1 study

**P089 (0137)**
Population pharmacokinetic (POPPK) modeling and exposure-response (ER) assessment of brentuximab vedotin efficacy and safety in patients with advanced classical Hodgkin Lymphoma (cHL) from the phase 3 Echelon-1 study

**P090 (0141)**
PET–CT as a prognostic factor in patients with advanced stages in primary diagnosed Hodgkin Lymphoma (HL)
Session 7: Pediatric Hodgkin Lymphoma

Talk

P091 (0159)
Serum sCD30 and TARC do not correlate with PET-based response assessment in patients (pts) with stage III or IV classical Hodgkin lymphoma (cHL): phase 3 Echelon-1 study of brentuximab vedotin plus chemotherapy vs chemotherapy alone

Posters

P092 (0019)
Proteomic identification of plasma biomarkers in children and adolescents with recurrent Hodgkin Lymphoma

P093 (0028)
HOPE to COPE with OPPA/COPP: experience of GPOH HD-2002 study protocol in pediatric Hodgkin lymphoma in a tertiary care hospital in a resource constraint setting
Patra PC, Phukan A, Chakrabarti P, Mandal PK, Dolai TK, De R, Baul S

P094 (0059)
KEYNOTE-667: phase 2, open-label study of pembrolizumab in children and young adults with newly diagnosed classical Hodgkin lymphoma (cHL) with slow early response (SER) to frontline chemotherapy
Mauz-Körholz C, Kelly K, Keller F, Nahar A, Balakumaran A, Giulino-Roth L

P095 (0064)
Hodgkin's Lymphoma in adolescents: the Italian Association of Pediatric Hematology and Oncology (AIEOP) experience

P096 (0085)
M1 macrophage polarization prevails in pediatric Hodgkin lymphoma from Argentina regardless of Epstein Barr virus presence
P097 (0105)
Implementing an effective pre-accrual quality assurance programme in the UK to ensure accuracy and consistency of radiotherapy contouring for paediatric Hodgkin’s lymphoma within the EuroNet-PHL-C2 trial (EudraCT 2012-004053-88)
Diez P, Gallop-Evans E, Cutter DJ, Chang YC, Sivabalasingham S, Ajithkumar T, Hedegaard DL, Hayward J, Daw S

P098 (0111)
Treatment outcomes of adolescent and young adult (AYA) Hodgkin Lymphomas (HL): real world data from a tertiary care cancer centre

P099 (0117)
Survival by age in children and adolescents with Hodgkin lymphoma: a pooled analysis of Children’s Oncology Group (COG) trials
Kahn JM, Kelly KM, Pei Q, Friedman DL, Keller F, Bush R, Bhatia S, Henderson TO, Schwartz CL, Castellino SM

P100 (0119)
FAMHL: genetic study of families with a high frequency of classical Hodgkin lymphoma

P101 (0149)
Phase 1/2 study of brentuximab vedotin plus AVD in pediatric patients with advanced stage newly diagnosed classical Hodgkin lymphoma

P102 (0151)
Durable remission for two patients with early relapse of Hodgkin Lymphoma, treated with brentuximab vedotin plus Gemcitabine, without autologous stem cell transplantation: a report from the Children’s Oncology Group

P103 (0152)
Stanford V chemotherapy and low dose radiotherapy for children and adolescents with unfavorable and intermediate risk Hodgkin Lymphoma: results of a multi-institutional prospective clinical trial

Session 8: Immunotherapy – Clinical

Talk

T025 (0005)
Brentuximab Vedotin in combination with Nivolumab in patients with relapsed or refractory Hodgkin lymphoma: follow-up results from the phase 1/2 study

T026 (0025)
A phase II study of SHR-1210, an anti-PD-1 antibody, in Chinese patients with relapsed/refractory classic Hodgkin lymphoma

T027 (0153)
Phase 2 Study of Frontline Brentuximab Vedotin Plus Nivolumab in Patients with Hodgkin Lymphoma Aged ≥60 Years
Allogeneic stem cell transplantation (allo-SCT) for relapsed/refractory classical Hodgkin lymphoma (cHL) patients treated with Nivolumab is associated with an unprecedented low relapse rate.


A phase II study of pembrolizumab (pem) followed by AVD for frontline treatment of classical Hodgkin lymphoma (cHL): interim results.


Nivolumab in relapsed/refractory classic Hodgkin lymphoma: Experience with ten patients.

Dada R, Zabani Y

Bendamustine, gemcitabine, and dexamethasone (BGD) chemotherapy followed by autologus stem cell transplantation (ASCT) is effective treatment for patients with relapsed/refractory Hodgkin lymphoma (rHL) – Results of the Polish lymphoma Research Group (PLRG) pilot study – Pre-PLRG-HL1 (BURGUND).


Five-year progression-free survival outcomes from a pivotal phase 3 study of consolidative Brentuximab Vedotin after autologous stem cell transplant in patients with Hodgkin lymphoma at risk of relapse or progression (AETHERA).


Relapse after early-stage favorable Hodgkin lymphoma: disease characteristics, treatment strategies and their outcome.

**Poster Pitch**

**P118 (0068)**
Long term safety and efficacy of combination of brentuximab vedotin and ipilimumab or nivolumab in relapsed/refractory Hodgkin Lymphoma: a trial of the ECOG–ACRIN Cancer Research Group (E4412)

**P126 (0121)**
PD-1 blockade for Hodgkin Lymphoma after allogeneic stem cell transplantation

**Posters**

**P108 (0001)**
Allogeneic stem cell transplantation after treatment with checkpoint inhibitors: feasibility and safety in pooled analysis
Dada R, Usman B

**P109 (0012)**
High CR rate in interim results of a phase II trial of Nivolumab with or without ICE in relapsed/refractory HL prior to AHCT

**P110 (0014)**
Successful treatment of Hodgkin Lymphoma with brentuximab vedotin relapsing after autologous stem cell transplantation
Markova J, Mocikova H, Gaherova L, Kozak T, on behalf of the Czech Hodgkin Lymphoma Study Group

**P111 (0017)**
Time to relapse in nodular lymphocyte-predominant Hodgkin Lymphoma is related to the histopathological pattern at initial diagnosis and relapse

**P112 (0020)**
A phase II study with bendamustine plus brentuximab vedotin in Hodgkin’s Lymphoma in first salvage setting: the BBV regimen

**P113 (0040)**
Phase I/II study of Brentuximab vedotin in first refractory/relapsed classical Hodgkin Lymphoma patients treated by chemotherapy (ICE) before autologous transplantation
Stamatoullas A, Ghesquieres H, Perrot A, Quittet P, Morschhauser F, Ribrag V, Edeline V, Brice P, for the LYSA group

**P114 (0041)**
Results of Mini-BEAM as second salvage chemotherapy after DHAP based chemotherapy for relapsed or refractory classical Hodgkin lymphoma
Veldman C, Nijland M, van Meerten T, Hoogendoorn M, Huls GW, Plattel WJ

**P115 (0048)**
Brentuximab vedotin (BV) as maintenance or salvage therapy after ASCT for relapsed/refractory (R / R) HL

**P116 (0054)**
Early transplant related complications in Hodgkin Lymphoma patients receiving PD-1 inhibitors before allogeneic stem cell transplantation
de Philippis C, Mariotti J, Bramanti S, Sarina B, Magagnoli M, Morello L, Santoro A, Carlo-Stella C, Castagna L
P117 (0063)
Bendamustine in heavily pre-treated Hodgkin lymphoma patients
Pavlov VV, Falaleeva NA, Bogatyreva TI, Shklyaev SS, Terekhova AY, Volodina OM

P119 (0078)
Real life data of brentuximab vedotin use in relapsed/refractory HL in Sweden

P120 (0086)
Outcomes and toxicities after brentuximab vedotin (BV) maintenance in relapsed/refractory Hodgkin lymphoma patient exposed to BV prior to autologous hematopoietic stem cell transplant

P121 (0089)
Sequential time-intensified brentuximab vedotin (BV) followed by gemcitabine, vinorelbine and pegylated liposomal doxorubicine (GVD) as a bridge to autologous transplantation in DHAP resistant relapsed or refractory CD30+ lymphoma
Cernauskiene S, Semaskeviciene R, Mickeviciute O, Griskevicius L

P122 (0090)
Brentuximab vedotin prior to allogeneic transplantation in Hodgkin’s lymphomas reduces chronic GVHD without worsening the outcome

P123 (0107)
Next generation sequencing-based clonality assessment of immunoglobulin gene rearrangements distinguishes relapse from second primary Hodgkin lymphoma

P124 (0115)
Retrospective real-life study of the BEGEV (bendamustine, gemcitabine, vinorelbine) regimen in heavily pretreated, relapsed/refractory classical Hodgkin lymphoma patients

P125 (0116)
Nivolumab re-treatment in patients with relapsed/refractory Hodgkin lymphoma

P127 (0126)
Autologous (auto-HCT) and allogeneic stem cell transplantation (allo-HCT) in the management of relapsed/refractory (RR) Hodgkin lymphoma (HL). A retrospective analysis of the Lymphoma Working Party of the EBMT

P128 (0127)
Successful slow desensitization to brentuximab vedotin after anaphylaxis: 3 case reports in the Basque autonomous community
Otero Longo I, Aranbarri Larrañaga A, Caminos Altuna N, Martinez Molina S, Joral Badas A, Ondarra Segurola L

P129 (0128)
Clinical analysis of relapse patterns in Hodgkin lymphoma

P130 (0132)
Primary progressive classical Hodgkin lymphoma – A single centre experience
Afonso C, Roque A, Neves D, Pinto A, Mota D, Guilherme R, Gomes M, Ribeiro L
P131 (0133)
Pooled results of two annual cohorts from an observational prospective study describing brentuximab vedotin use in routine practice in France for Hodgkin Lymphoma: interim analysis

P132 (0138)
Patterns and outcomes with salvage treatment for Hodgkin Lymphoma (HL) in the modern era: a real-world analysis from the community oncology setting in the United States
Kumar AJ, Chao CR, Rodday AM, Cannizzaro NT, Rodriguez R, Feliciano J, Evans AM, Parsons SK

P133 (0148)
Prognostic value of (18) f-fluorodeoxyglucose-positron emission tomography on survival in Hodgkin Lymphoma patients treated with allogeneic stem cell transplantation

P134 (0156)
Induction therapy with everolimus in combination with DHAP (dexamethasone, high-dose arac, cisplatinum) in patients with relapsed or refractory classical Hodgkin Lymphoma: a randomized, placebo-controlled phase III trial (HD-R3i)

P135 (0160)
Brentuximab vedotin + bendamustine: a highly effective salvage treatment on refractory/relapsed patients with Hodgkin Lymphoma

P136 (0161)
Long term outcome of patients with relapsed/refractory Hodgkin Lymphoma treated at a single institution over 25 years

P137 (0165)
Treatment strategies and prognostic factors for the outcome of very late relapses (VLRs) occurring ≥5 years after initial treatment with chemotherapy ± radiotherapy (CT±RT) in Hodgkin Lymphoma (HL): a joint study from the University of Athens and Istituto Nazionale dei Tumori Milano
*TPV and AL had equal contribution to this work

P138 (0167)
Long-term high dose chemotherapy before hematopoietic stem cell transplantation due to restricted access to new therapies

P139 (0169)
Brentuximab vedotin alone and in combination with bendamustine as salvage therapy for primary refractory or relapsed Hodgkin Lymphoma: multicentre experience of the Polish Lymphoma Research Group
Advani, Ranjana: radvani@stanford.edu
Allen, Pamela: pamela.b.allen@emory.edu
André, Marc: marc.andre@uclouvain.be
Ansell, Stephen: ansell.stephen@mayo.edu
Armand, Philippe: Philippe_Armand@dfci.harvard.edu
Baiocchi, Otavio: obaiocchi@gmail.com
Barrington, Sally: sally.barrington@kcl.ac.uk
Baues, Christian: christian.baues@uk-koeln.de
Böll, Boris: boris.boell@uk-koeln.de
Borchmann, Peter: Peter.Borchmann@uni-koeln.de
Borchmann, Sven: sven.borchmann@uk-koeln.de
Bräuninger, Andreas: Andreas.Braeuninger@patho.med.uni-giessen.de
Brice, Pauline: Pauline.Brice@sls.aphp.fr
Bröckelmann, Paul J.: Paul.Broeckelmann@uk-koeln.de
Casagrande, Naike: naike.casagrande@libero.it
Casasnovas, Olivier: olivier.casasnovas@chu-dijon.fr
Castagna, Luca: luca.castagna@cancercenter.humanitas.it
Constine, Louis: Louis_Constine@urmc.rochester.edu
Cuccaro, Annarosa: annarosa.cuccaro@gmail.com
Dabaja, Bouthaina: bdabaja@mdanderson.org
Delfau-Larue, Marie-Hélène: marie-helene.delfau@hmn.aphp.fr
Diehl, Volker: v.diehl@uni-koeln.de
Dietlein, Markus: markus.dietlein@uk-koeln.de
Drees, Esther: e.drees@vumc.nl
Eichenauer, Dennis A.: dennis.eichenauer@uk-koeln.de
Engert, Andreas: a.engert@uni-koeln.de
Evens, Andrew: ae378@cinj.rutgers.edu
Fiaccadori, Valeria: valeria.fiaccadori.17@ucl.ac.uk
Fosså, Alexander: aff@ous-hf.no
Friedberg, Jonathan: jonathan_friedberg@urmc.rochester.edu
Gallamini, Andrea: andreagallamini@gmail.com
Gandhi, Maher K.: m.gandhi@uq.edu.au
Gattenlöhner, Stefan: stefan.gattenloehner@patho.med.uni-giessen.de
Geissler, Jan: jan@cmladvocates.net
Glimelius, Ingrid: Ingrid.Glimelius@igp.uu.se
Gotti, Manuel: manuel.gotti@hotmail.it
Ha, Chul S.: hac@uthscsa.edu
Hagenbeek, Anton: a.hagenbeek@amc.uva.nl
Hansmann, Martin-Leo: m.l.hansmann@em.uni-frankfurt.de
Hartmann, Sylvia: s.hartmann@em.uni-frankfurt.de
Henke, Oliver: oliver.henke@charite.de
Herrera, Alex: aherrera@coh.org
Hertzberg, Marc: mhertzberg10@gmail.com
Hoppe, Richard: Richard.Hoppe@stanford.edu
Hutchings, Martin: hutchings@dadlnet.dk
Illidge, Tim: Tim.Illidge@ics.manchester.ac.uk
Johnson, Peter: Johnsonp@soton.ac.uk
Kahn, Justine: jk2034@cumc.columbia.edu
Karihtala, Kristiina: kristiina.karihtala@gmail.com
Kelly, Kara: Kara.Kelly@RoswellPark.org
Kinley, Judith: judith.kinley@takeda.com
Klapper, Wolfram: wklapper@path.uni-kiel.de
Knoop, Hans: hans.knoop@amc.uva.nl
Kobe, Carsten: carsten.kobe@uk-koeln.de
Küppers, Ralf: ralf.kueppers@uk-essen.de
Lister, Andrew: a.lister@qmul.ac.uk
Lollies, Anna: anna.lollies@uk-essen.de
Lynch, Ryan: rclynch@uw.edu
Maraldo, Maja: maja.vestmoe.maraldo@regionh.dk
Marnitz-Schulze, Simone: simone.marnitz-schulze@uk-koeln.de
Martínez, Carmen: cmarti@clinic.ub.es
Mauz-Körholz, Christine:
christine.mauz-koerholz@paediat.med.uni-giessen.de
Meignan, Michel: michel.meignan@aphp.fr
Metzger, Monika: monika.metzger@stjude.org
Morton, Lindsay: mortonli@mail.nih.gov
Moskowitz, Craig H.: CHM78@miami.edu
Mottok, Anja: anja.mottok@uni-ulm.de
Parsons, Susan: sparsons@tuftsmedicalcenter.org
Paszkiewicz-Kozik, Ewa: epaszkiewicz@coi.waw.pl
Warwick, Lorna: lorna@lymphomacoalition.org
Plate, Ananda: plate@mpeurope.org
Radford, John: John.Radford@manchester.ac.uk
Raemaekers, John: johnmienraemaekers@gmail.com
Rassidakis, George: georgios.rassidakis@ki.se
Romejko-Jarosinska, Joanna: jaroinska@coi.waw.pl
Roschewski, Mark: mark/roschewski@nih.gov
Rosenwald, Andreas: rosenwald@uni-wuerzburg.de
Rossi, Davide: davide.rossi@ior.iosi.ch
Shipp, Margaret: Margaret_shipp@dfci.harvard.edu
Song, Yuqin: songyuqin622@163.com
Specht, Lena: specht@rh.dk
Steidl, Christian: CSteidl@bccancer.bc.ca
Sureda, Anna: asureda@iconcologia.net
Torres Viera, Maria Alejandra: matorresviera@gmail.com
Tucci, Allessandra: alessandra.tucci@asst-spedalicivili.it
van den Berg, Anke: a.van.den.berg01@umcg.nl
van Leeuwen, Flora: f.v.leeuwen@nki.nl
Visentin, Andrea: andrea.visentin@aopd.veneto.it
West, Catharine: catharine.west@manchester.ac.uk
Wojnowski, Leszek: wojnowski@uni-mainz.de
Yahalom, Joachim: yahalomi@mskcc.org
Yang, Jun: Jun.Yang@STJUDE.ORG
Yang, Joanna: joanna.c.yang@gmail.com
Zinzani, Pier Luigi: pierluigi.zinzani@unibo.it
YOUNG INVESTIGATOR AWARD

Annika Weiß | Ø P019  
Valeria Fiaccadori | Ø T012  
Nele Stadtbumer | Ø P060  
Ryan Lynch | Ø T017  
Justine Kahn | Ø T022

KARL MUSSHOFF PRIZE
Basic and Translational Science

The Karl Musshoff Foundation was established by Professor Karl Musshoff in 1997. The Karl Musshoff Prize is granted during ISHL in Cologne for outstanding results and a life-long contribution to the field of Hodgkin Lymphoma.

This year’s prize in the category “Basic and Translational Science” will be awarded to:

RALF KÜPPERS

KARL MUSSHOFF PRIZE
Clinical Research

The Karl Musshoff Foundation was established by Professor Karl Musshoff in 1997. The Karl Musshoff Prize is granted during ISHL in Cologne for outstanding results and a life-long contribution to the field of Hodgkin Lymphoma.

This year’s prize in the category “Clinical Research” will be awarded to:

RICHARD HOPPE
We would very much like to thank all of our partners for their generous sponsoring.

<table>
<thead>
<tr>
<th>Name of Sponsor</th>
<th>Total Sponsoring Amount</th>
<th>Sponsoring Benefit</th>
</tr>
</thead>
<tbody>
<tr>
<td>AstraZeneca GmbH</td>
<td>€ 4,000.00</td>
<td>Booth</td>
</tr>
<tr>
<td>Bristol-Myers Squibb</td>
<td>€ 52,000.00</td>
<td>Symposium / Booth / Advertisement Final Program</td>
</tr>
<tr>
<td>Celgene GmbH</td>
<td>€ 22,500.00</td>
<td>Symposium</td>
</tr>
<tr>
<td>Chugai Pharma Europe Ltd.</td>
<td>€ 22,500.00</td>
<td>Symposium</td>
</tr>
<tr>
<td>Sandoz Germany</td>
<td>€ 32,000.00</td>
<td>Symposium</td>
</tr>
<tr>
<td>Merck &amp; Co., Inc.</td>
<td>€ 8,000.00</td>
<td>Booth</td>
</tr>
<tr>
<td>MSD SHARP&amp;DOHME GMBH</td>
<td>€ 32,000.00</td>
<td>Symposium</td>
</tr>
<tr>
<td>Mundipharma EDO GmbH</td>
<td>€ 4,000.00</td>
<td>Advertisement</td>
</tr>
<tr>
<td>Novartis Pharma GmbH</td>
<td>€ 4,000.00</td>
<td>Booth</td>
</tr>
<tr>
<td>Roche Pharma AG</td>
<td>€ 4,000.00</td>
<td>Booth</td>
</tr>
<tr>
<td>Sanofi Genzyme GmbH</td>
<td>€ 4,000.00</td>
<td>Booth</td>
</tr>
<tr>
<td>Takeda Oncology</td>
<td>€ 80,000.00</td>
<td>2 Symposia / Booth / Advertisement Final Program</td>
</tr>
</tbody>
</table>

Seattle Genetics and Takeda Oncology are leading the way to a better understanding of classical Hodgkin lymphoma by expanding knowledge around the biological development of the disease and the critical role of CD30. By driving science forward, we are helping to address the unanswered questions to improve the treatment of Hodgkin lymphoma.

Our commitment to advancing care for people living with Hodgkin lymphoma is demonstrated by more than 50 clinical trials, including two large, randomized, phase III company-sponsored studies. We take pride in providing unparalleled support for clinical research in Hodgkin lymphoma with the goal of improving outcomes for patients around the world.

Patients are at the center of our mission. We work alongside advocacy groups to improve the patient experience and outcomes by advancing education and identifying and addressing their unmet needs.

Join our journey at the forefront of science, progress, and care by visiting us at our booth at ISHL.
OPDIVO® – Approved for Relapsed or Refractory Classical Hodgkin’s Lymphoma¹

OPDIVO as monotherapy is indicated for the treatment of adult patients with relapsed or refractory classical Hodgkin lymphoma after autologous stem cell transplant (ASCT) and treatment with brentuximab vedotin.

References: 1. OPDIVO® Summary of Product Characteristics. ©2018 Bristol-Myers Squibb Company. All rights reserved. OPDIVO® and the related logos are trademarks of Bristol-Myers Squibb Company. 1506DE1804914-01 Date of preparation: August 2018

German and English Summary of Product Characteristics are available at the booth.

Brilliant Opportunities

GIVE MORE PATIENTS
THE OPDIVO OPPORTUNITY.

Bristol-Myers Squibb
SAVE THE DATE
12th International Symposium on Hodgkin lymphoma
October 2020

Further information will be available at www.hodgkinsymposium.org